Literature DB >> 7820549

The activation of phosphatidylinositol 3-kinase by Ras.

T Kodaki1, R Woscholski, B Hallberg, P Rodriguez-Viciana, J Downward, P J Parker.   

Abstract

BACKGROUND: Activation of the mammalian phosphatidylinositol 3-kinase complex can play a critical role in transducing growth factor responses. The lipid kinase complex, which is made up of p85 alpha and p110 alpha regulatory and catalytic subunits, becomes associated with a number of activated receptor protein tyrosine kinases, but the mechanism of its activation has not yet been defined. Recent evidence indicates that Ras can bind to the p85 alpha/p110 alpha complex. We describe here the functional regulation of the mammalian phosphatidylinositol 3-kinase complex by Ras.
RESULTS: Expression of p110 alpha, the catalytic subunit of phosphatidylinositol 3-kinase, in the fission yeast, Schizosaccharomyces pombe, has been used to demonstrate an inhibitory effect of p85 alpha on p110 alpha activity in intact cells; inhibition did not result from a decrease in p110 alpha expression. In this cellular context, we have investigated the effect of a constitutively active mutant of Ras, v-Ras, either on p85 alpha or p110 alpha-alone, or on the p85 alpha/p110 alpha complex. In the presence of the p85 alpha/p110 alpha complex, v-Ras suppressed cell growth, but an effector-domain mutant of v-Ras did not. The growth-suppressive effect of v-Ras was not seen for any other combination of expressed proteins. The phenotype induced by v-Ras was consistent with activation of the p85 alpha/p110 alpha complex: it was sensitive to the phosphatidylinositol 3-kinase inhibitor, wortmannin, and the cells accumulated 3-phosphorylated polyphosphoinositides. Activation of purified p85 alpha/p110 alpha by purified recombinant Ras in vitro was also demonstrated.
CONCLUSIONS: The phosphatidylinositol 3-kinase complex, p85 alpha/p110 alpha, shows a suppressed catalytic function in vivo when compared with free p110 alpha. This complex can, however, be activated by Ras. We suggest that the phosphatidylinositol 3-kinase p85 alpha/p110 alpha complex is a downstream effector of Ras.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7820549     DOI: 10.1016/s0960-9822(00)00177-9

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  93 in total

1.  Phosphatidylinositol 3-kinase mediates epidermal growth factor-induced activation of the c-Jun N-terminal kinase signaling pathway.

Authors:  S K Logan; M Falasca; P Hu; J Schlessinger
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

2.  Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.

Authors:  Haiyan Wu; S Chandra Shekar; Rory J Flinn; Mirvat El-Sibai; Bijay S Jaiswal; K Ilker Sen; Vasantharajan Janakiraman; Somasekar Seshagiri; Gary J Gerfen; Mark E Girvin; Jonathan M Backer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-13       Impact factor: 11.205

3.  A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy.

Authors:  J B Pracyk; K Tanaka; D D Hegland; K S Kim; R Sethi; I I Rovira; D R Blazina; L Lee; J T Bruder; I Kovesdi; P J Goldshmidt-Clermont; K Irani; T Finkel
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

4.  Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase.

Authors:  C Jimenez; D R Jones; P Rodríguez-Viciana; A Gonzalez-García; E Leonardo; S Wennström; C von Kobbe; J L Toran; L R-Borlado; V Calvo; S G Copin; J P Albar; M L Gaspar; E Diez; M A Marcos; J Downward; C Martinez-A; I Mérida; A C Carrera
Journal:  EMBO J       Date:  1998-02-02       Impact factor: 11.598

5.  Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B.

Authors:  Sébastien Jeay; Stefania Pianetti; Herbert M Kagan; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

6.  Improved binding of raf to Ras.GDP is correlated with biological activity.

Authors:  Christina Kiel; Daniel Filchtinski; Michael Spoerner; Gideon Schreiber; Hans Robert Kalbitzer; Christian Herrmann
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

7.  Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.

Authors:  Miriam Molina-Arcas; David C Hancock; Clare Sheridan; Madhu S Kumar; Julian Downward
Journal:  Cancer Discov       Date:  2013-03-01       Impact factor: 39.397

8.  Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.

Authors:  Bijay S Jaiswal; Vasantharajan Janakiraman; Noelyn M Kljavin; Subhra Chaudhuri; Howard M Stern; Weiru Wang; Zhengyan Kan; Hashem A Dbouk; Brock A Peters; Paul Waring; Trisha Dela Vega; Denise M Kenski; Krista K Bowman; Maria Lorenzo; Hong Li; Jiansheng Wu; Zora Modrusan; Jeremy Stinson; Michael Eby; Peng Yue; Josh S Kaminker; Frederic J de Sauvage; Jonathan M Backer; Somasekar Seshagiri
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

9.  Rac GTPase interacts specifically with phosphatidylinositol 3-kinase.

Authors:  G M Bokoch; C J Vlahos; Y Wang; U G Knaus; A E Traynor-Kaplan
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

10.  PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.

Authors:  Frank Schönleben; Wanglong Qiu; Helen E Remotti; Werner Hohenberger; Gloria H Su
Journal:  Langenbecks Arch Surg       Date:  2008-02-21       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.